Figure 3. SUMOs colocalize with familial ALS-linked SOD1 mutants in intracellular aggregates.
Image credit: Niikura, et. al. 2014 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! TREAT ALS Clinical Management Grant
Sponsor: ALS Association
Description: The aim of the ALS Association TREAT ALS Clinical Management Grant Program is to improve care and living with ALS with a focus on clinical, psychological and or social management of ALS. The maximum award is $100,000 per year for up to 2 years.
Deadline: Abstracts due by June 11, 2018.



NEW! AHA and Allen Initiative in Brain Health and Cognitive Impairment
Sponsor: American Heart Association and the Paul G. Allen Frontiers Group
Description: The AHA and Paul G. Allen Frontiers Group, with additional funding contributors including the Oskar Fischer Project, will grant a competitive basic science research award(s) of up to $43 million over eight years to one or more highly inspiring and innovative integrated team(s). New frontiers of discovery in brain health, and more specifically in cognitive impairment, will be opened when expertise and novel advances are shared and leveraged among basic and clinical cerebrovascular scientists and neuroscientists. Such integrative studies have the potential to bring truly novel directions of inquiry to the current incremental progress in the field of neurodegeneration.
Deadline: Application due by July 6, 2018.



NEW! Harrington Rare Disease Scholar Award
Sponsor: Harrington Discovery Institute
Description: The Harrington Rare Disease Scholar Award was created to advance breakthrough research into novel treatments for rare diseases. The Harrington Rare Disease Scholar Program will provide funding and hands-on drug development guidance for two years to U.S.-based PhD and MD researchers whose discoveries show promise for translation into novel medicines for rare diseases. Up to 1M USD will be awarded.
Deadline: Letter of Intent due by July 2018.



NEW! Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases
Sponsor: NINDS
Description: The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients. Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials. The studies supported through this FOA should be clinical observational studies. No interventional studies will be supported via this funding mechanism.
Deadline: Application due by August 17, 2018.



New Investigator Research Grant, Neuroscience (UK)
Sponsor: MRC
Description: The New Investigator Research Grant (NIRG) is aimed at researchers who are capable of becoming independent Principal Investigators and who are now ready to take the next step towards that goal. A NIRG is normally of three years duration and is not renewable.
Deadline: Application due by May 30, 2018.



MDA Venture Philanthropy Program
Sponsor: Muscular Dystrophy Association
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is  $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by June 1, 2018.



ALS Canada Project Grant Program
Sponsor: ALS Canada
Description: This grant program funds the best projects including high risk/high reward with little preliminary data, continuation of ongoing high quality research and studies to improve the quality of life for people with ALS. Grants anticipated to be $125,000 CAD for use over 1 or 2 years.
Deadline: Application due by June 8, 2018.



Eppendorf & Science Prize for Neurobiology
Sponsor: Eppendorf & Science
Description: The International Eppendorf & Science Prize for Neurobiology is awarded annually to one young scientist for the most outstanding neurobiological research based on methods of molecular and cell biology conducted by him/her during the past three years. The award: $25,000 USD.
Deadline: Application due by June 15, 2018.



Research Grants
Sponsor: Muscular Dystrophy Association
Description: These grants are awarded to independent, established investigators to accelerate progress toward understanding and treating diseases that are neuromuscular in nature including ALS. The total award is $100,000 per year for one to three years. In a very limited number of cases, awards will exceed $100,000 per year, but pre-approval is required before letter of intent submission.
Deadline: Letter of Intent due by June 15, 2018.



ALSRP Therapeutic Development Award
Sponsor: US Department of Defense CDMRP
Description: The goal of the Amyotrophic Lateral Sclerosis Research Program is to fund innovative preclinical research to promote the development of new treatments that may contribute to a cure for ALS. The anticipated direct costs budgeted for the entire period of performance for an FY18 ALSRP Therapeutic Development Award will not exceed $1,000,000 USD, or $1,250,000 USD if applying under the Therapeutically Relevant Marker Option.
Deadline: Application due by June 22, 2018.



ALSRP Therapeutic Idea Award
Sponsor: US Department of Defense CDMRP
Description: The goal of the ALSRP is to fund innovative preclinical research to promote the development of new treatments that may contribute to a cure for ALS. The anticipated direct costs budgeted for the entire period of performance for an FY18 ALSRP Therapeutic Idea Award will not exceed $500,000 USD.
Deadline: Application due by June 22, 2018.



Scientific Innovations Award
Sponsor: Brain Research Foundation
Description: The Scientific Innovations Award supports innovative discovery science in both basic and clinical neuroscience. This funding mechanism is designed to support creative, cutting edge research in well-established research laboratories, under the direction of established investigators.
Deadline: Letter of Intent due by June 22, 2018.



Roger de Spoelberch Prize
Sponsor: Roger de Spoelberch Foundation
Description: Each year, the Foundation awards the Roger de Spoelberch Prize to a winner for a clinical and basic scientific research project in the area of neurodegenerative diseases and psychiatric disorders. The value of the prize currently amounts to 750,000 euros.
Deadline: Application due by June 29, 2018.



Nonclinical and Early-Phase Clinical Development for Biologics
Sponsor: NINDS, CREATE Bio Development Track
Description: This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial will be funded. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA).
Deadline: Application due by July 18, 2018.



Tools to target, identify and characterize non-neuronal cells in the brain.
Sponsor: NIH BRAIN Initiative
Description: The purpose of this Funding Opportunity Announcement [FOA] submitted through the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to stimulate the development and validation of novel tools and analytical methods to target, identify and characterize non-neuronal cells in the brain.
Deadline: Letter of Intent due by September 4, 2018.



Frick Foundation for ALS Research Award
Sponsor: Bruno and Ilse Frick Foundation for Research on ALS
Description: The aim of the Foundation is to encourage basic biomedical research related to understanding the cause of ALS. The funding is 100,000 CHF over 2 years.
Deadline: Application due by October 8, 2018.



ADDF NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



Early Phase Clinical Trials, Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years.
Deadline: Applications will be accepted on a rolling basis.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Transformational Research: Canada 2018
Sponsor: Weston Brain Institute
Description: This program funds transformative, novel, high-risk, high-reward translational research projects with excellent preliminary data aimed at accelerating the development of therapies for neurodegenerative diseases of aging including FTD. A maximum of $1,500,000 over up to 3 years per project. PIs must be at or above the level of Assistant Professor or equivalent, work in Canada at least 30% of the time, and be affiliated with a CRA-qualified institution.
Deadline: February 15, 2018 (extended).



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail